On Friday, NeoGenomics earned a positive adjustment to its Relative Strength (RS) Rating, from 72 to 81.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
While NeoGenomics is not near a proper entry right now, see if it goes on to form and break out from a proper consolidation.
NeoGenomics reported 0% EPS growth last quarter. Revenue increased 10%.
The company earns the No. 6 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Castle Biosciences and NeoGenomics are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
